Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Calliditas Therapeutics

CALT
Current price
38.77 USD -0.23 USD (-0.59%)
Last closed 39.07 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 051 959 744 USD
Yield for 12 month +110.14 %
1Y
3Y
5Y
10Y
15Y
CALT
21.11.2021 - 28.11.2021

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. Address: Kungsbron 1, D5, Stockholm, Sweden, 111 22

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

35.5 USD

P/E ratio

Dividend Yield

Current Year

+113 516 274 USD

Last Year

+75 516 396 USD

Current Quarter

+42 472 477 USD

Last Quarter

+42 472 477 USD

Current Year

+106 268 523 USD

Last Year

+74 086 636 USD

Current Quarter

+40 375 099 USD

Last Quarter

+40 375 099 USD

Key Figures CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -409 569 984 USD
Operating Margin TTM -68.98 %
PE Ratio
Return On Assets TTM -14.9 %
PEG Ratio
Return On Equity TTM -147.93 %
Wall Street Target Price 35.5 USD
Revenue TTM 1 311 016 960 USD
Book Value
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 54.4 %
Dividend Yield
Gross Profit TTM 787 678 000 USD
Earnings per share -1.87 USD
Diluted Eps TTM -1.87 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -40.03 %

Dividend Analytics CALT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CALT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 18.3824
Enterprise Value Revenue 0.4267
Price Sales TTM 0.4522
Enterprise Value EBITDA -1.3804
Price Book MRQ 16.341

Financials CALT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CALT

For 52 weeks

15.25 USD 41.9 USD
50 Day MA 25.32 USD
Shares Short Prior Month 9 774
200 Day MA 21.27 USD
Short Ratio 1.55
Shares Short 8 233
Short Percent 0.27 %

Dynamics of changes in the value of assets

Stocks


AAPL

AAPL

212.49 USD Apple Inc -1.32 (-0.62%)
Detailed analytics

ETF funds


S

SX7EEX

13.36 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.53 (-3.54%)
Detailed analytics

Metals


Gold

2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics